4-[(3R,5R,6S,7S,10R,13R)-3,6,7-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 4-[(3R,5R,6S,7S,10R,13R)-3,6,7-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
• 化学式: C₂₄H₄₀O₅
• 分子量: 408.6
• InChiKey: DKPMWHFRUGMUKF-QFCFZQQBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  98
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• METHOD FOR DETERMININGIN VITRO
  申请人：Clayton Pharmaceuticals LLC

  公开号：EP3423829A1

  公开（公告）日：2019-01-09
• METHOD FOR DETERMINING IN VITRO BIOEQUIVALENCE OF A SUCRALFATE SUSPENSION SAMPLE TO A SUCRALFATE SUSPENSION REFERENCE LISTED DRUG (RLD)
  申请人：Clayton Pharmaceuticals LLC

  公开号：EP3423829B1

  公开（公告）日：2020-10-28
• COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS
  申请人：Uysal Teoman

  公开号：US20090131384A1

  公开（公告）日：2009-05-21

  The invention provides novel compounds, methods for treating or preventing a condition related to ER-stress, e.g. hypercholesterolemia, atherosclerosis and related conditions, and pharmaceutical compositions related thereto.
• US9989519B1
  申请人：——

  公开号：US9989519B1

  公开（公告）日：2018-06-05
• [EN] MURICHOLIC ACID-BASED COMPOUNDS AS INHIBITORS OF CLOSTRIDIUM DIFFICILE SPORE GERMINATION<br/>[FR] COMPOSÉS À BASE D'ACIDE MURICHOLIQUE SERVANT D'INHIBITEURS DE GERMINATION DE SPORES DE CLOSTRIDIUM DIFFICILE
  申请人：TEXAS A & M UNIV SYS

  公开号：WO2015076788A1

  公开（公告）日：2015-05-28

  The present invention relates to pharmaceutical compositions containing muricholic acid-based compounds, as well as methods of treatment, and methods of screening that use these compounds and compositions.